Aspen Neuroscience to Sell 9.4 Million Shares at $15-$17 Each in IPO

What happened

Aspen Neuroscience plans to sell nearly 9.4 million shares at $15 to $17 each in its initial public offering, expecting about $134.5 million in net proceeds at the $16 midpoint. It applied to list on Nasdaq under the symbol ASPE.

Confirmed

Global impact / market context

The IPO would give Aspen cash to fund its work on treatments for neurodegenerative diseases, which are brain and nerve disorders, into the second half of 2028. Investors are being asked to back a clinical-stage company that likely has little or no product revenue.

Analyst inference

At $16 a share and with nearly 30.5 million shares outstanding after the offering, Aspen would be valued at about $488 million. That is a modest size for a new listing, so demand from IPO buyers, not broad market moves, will likely set the final price.

Analyst inference

What to watch

1. Watch whether the shares price within the $15 to $17 range and whether underwriters buy the additional 1.41 million shares, since that option changes total proceeds. Confirmed
2. Track how much cash Aspen spends each quarter on research and trials, because the company says current funds last only into the second half of 2028. Analyst inference
3. Watch the final number of shares sold, since selling more than 9.4 million would dilute existing owners and lower profit per share for new buyers. Analyst inference

Evidence

• Original source link unavailable